233 related articles for article (PubMed ID: 27325647)
1. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
[TBL] [Abstract][Full Text] [Related]
2. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
[TBL] [Abstract][Full Text] [Related]
3. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.
Pham E; Birrer MJ; Eliasof S; Garmey EG; Lazarus D; Lee CR; Man S; Matulonis UA; Peters CG; Xu P; Krasner C; Kerbel RS
Clin Cancer Res; 2015 Feb; 21(4):808-18. PubMed ID: 25524310
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
Keefe SM; Hoffman-Censits J; Cohen RB; Mamtani R; Heitjan D; Eliasof S; Nixon A; Turnbull B; Garmey EG; Gunnarsson O; Waliki M; Ciconte J; Jayaraman L; Senderowicz A; Tellez AB; Hennessy M; Piscitelli A; Vaughn D; Smith A; Haas NB
Ann Oncol; 2016 Aug; 27(8):1579-85. PubMed ID: 27457310
[TBL] [Abstract][Full Text] [Related]
5. Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
Lin CJ; Lin YL; Luh F; Yen Y; Chen RM
Oncotarget; 2016 Jul; 7(27):42408-42421. PubMed ID: 27285755
[TBL] [Abstract][Full Text] [Related]
6. CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.
Tian X; Nguyen M; Foote HP; Caster JM; Roche KC; Peters CG; Wu P; Jayaraman L; Garmey EG; Tepper JE; Eliasof S; Wang AZ
Cancer Res; 2017 Jan; 77(1):112-122. PubMed ID: 27784746
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Voss MH; Hussain A; Vogelzang N; Lee JL; Keam B; Rha SY; Vaishampayan U; Harris WB; Richey S; Randall JM; Shaffer D; Cohn A; Crowell T; Li J; Senderowicz A; Stone E; Figlin R; Motzer RJ; Haas NB; Hutson T
Ann Oncol; 2017 Nov; 28(11):2754-2760. PubMed ID: 28950297
[TBL] [Abstract][Full Text] [Related]
8. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.
Gaur S; Wang Y; Kretzner L; Chen L; Yen T; Wu X; Yuan YC; Davis M; Yen Y
Nanomedicine; 2014 Oct; 10(7):1477-86. PubMed ID: 24768630
[TBL] [Abstract][Full Text] [Related]
10. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Krasner CN; Campos SM; Young CL; Chadda KR; Lee H; Birrer MJ; Horowitz NS; Konstantinopoulos PA; D'Ascanio AM; Matulonis UA; Penson RT
Gynecol Oncol; 2021 Sep; 162(3):661-666. PubMed ID: 34243976
[TBL] [Abstract][Full Text] [Related]
11. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models.
Schmidt KT; Chau CH; Strope JD; Huitema ADR; Sissung TM; Price DK; Figg WD
Mol Cancer Ther; 2021 May; 20(5):915-924. PubMed ID: 33632874
[TBL] [Abstract][Full Text] [Related]
13. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
14. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.
Eliasof S; Lazarus D; Peters CG; Case RI; Cole RO; Hwang J; Schluep T; Chao J; Lin J; Yen Y; Han H; Wiley DT; Zuckerman JE; Davis ME
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):15127-32. PubMed ID: 23980155
[TBL] [Abstract][Full Text] [Related]
15. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
Clark AJ; Wiley DT; Zuckerman JE; Webster P; Chao J; Lin J; Yen Y; Davis ME
Proc Natl Acad Sci U S A; 2016 Apr; 113(14):3850-4. PubMed ID: 27001839
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine.
Curigliano G; Bagnardi V; Bertolini F; Alcalay M; Locatelli MA; Fumagalli L; Rabascio C; Calleri A; Adamoli L; Criscitiello C; Viale G; Goldhirsch A
Breast; 2015 Jun; 24(3):263-71. PubMed ID: 25772326
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models.
Zheng H; Wu L; Chen J; Na N; Lou G
Breast Cancer; 2024 May; 31(3):371-381. PubMed ID: 38289410
[TBL] [Abstract][Full Text] [Related]
18. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
19. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
20. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]